Rhythm Pharmaceuticals (RYTM) Revenue (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Revenue data on file, last reported at $60.1 million in Q1 2026.

• Revenue for Q1 2026 came in at $60.1 million, up 83.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $217.2 million (up 58.67% YoY), and the FY2025 annual result was $189.8 million, up 45.83% from the prior year.
• Revenue advanced to $60.1 million in Q1 2026 per RYTM's latest filing, from $57.3 million in the prior quarter.
• Over five years, Revenue peaked at $60.1 million in Q1 2026 and troughed at -$8.0 million in Q4 2022.
• A 5-year average of $27.3 million and a median of $26.0 million in 2024 frame the typical range for Revenue.
• On a YoY basis, Revenue climbed as much as 4180.0% in 2022 and fell as far as 542.93% in 2022.
• A 5-year view of Revenue shows it stood at -$8.0 million in 2022, then surged by 401.12% to $24.2 million in 2023, then surged by 72.61% to $41.8 million in 2024, then jumped by 36.87% to $57.3 million in 2025, then gained by 4.99% to $60.1 million in 2026.
• Business Quant data shows RYTM's Revenue at $60.1 million in Q1 2026, $57.3 million in Q4 2025, and $51.3 million in Q3 2025.